US Biosimilar Spending Poised For Substantial Growth By 2024, IQVIA Says

 
• By Jessica Merrill

Biosimilar spending in the US is expected to increase from $5.2bn in 2019 to $27bn in 2024, driven by increased penetration and new biosimilar entries, including for Humira, according to an IQVIA report.

Turning Point sign with clouds and sky background
IQVIA says the US biosimilar market has hit an inflection point • Source: Shutterstock

More from Strategy

More from Business